Cardiovascular disease in patients with type 2 diabetes

Diabetes mellitus is treated pharmacologically, accompanied by lifestyle modifications, to achieve individualized glycemic goals. Reductions of acute hyperglycemic crises (diabetic ketoacidosis and hyperosmolar coma) are sought, as are the prevention or delay of chronic microvascular and macrovascular complications. There is no debate about whether glycemic control reduces the risk of microvascular complications. However, there is limited clinical evidence that glycemic control reduces cardiovascular disease.

One in three type 2 diabetes patients has cardiovascular disease, which is the leading cause of death. The mortality risk is twofold higher in patients with both diabetes and cardiovascular disease than in patients with diabetes alone. Notably, patients with recently diagnosed type 2 diabetes already have higher risks of death and cardiovascular disease than do individuals without diabetes. Thus, because morbidity and mortality in diabetes patients are generally attributable to cardiovascular disease, the prevention of such disease is a top priority in the treatment of diabetes. Along with glycemic control, several risk factors (hypertension, dyslipidemia, smoking and obesity) must be managed to prevent cardiovascular disease. Recently, some antidiabetic agents have been shown to reduce cardiovascular disease; clinical guidelines have been changed to encourage the use of such drugs.

The standard approach toward prevention of cardiovascular events in diabetes patients includes the control of blood glucose and lipid levels, blood pressure, and weight; all are known cardiovascular risk factors. An association between ethnicity (a non-traditional risk factor) and a high risk of cardiovascular disease has been suggested. Hyperglycemic events should be avoided considering the increased risk of cardiovascular events, particularly in elderly individuals. Recent works found that glycemic variability independently of hyperglycemia was a risk factor for both cardiovascular disease and microvascular complications.

Hyperglycemia-induced endothelial dysfunction and vascular damage are caused by oxidative stress and increased levels of pro-inflammatory cytokines; such problems are accentuated when glucose levels fluctuate.

Until recently, antidiabetic drugs initially were used to lower blood glucose levels and ultimately to prevent diabetic complications. A major change in this approach was triggered by the results of recent cardiovascular outcome trials, particularly in the participants of these studies (patients with type 2 diabetes and either established cardiovascular disease or a high risk of such disease). In patients with type 2 diabetes and established cardiovascular disease, heart failure or chronic kidney disease, the primary indications for sodium–glucose cotransporter 2 (SGLT2) inhibitors are evolving from targeted reduction of the glycosylated hemoglobin level to decreases in major atherosclerotic cardiovascular events, slower progression of renal failure and hospitalization for heart failure. The primary indications for glucagon-like peptide-1 receptor (GLP-1R) agonists are also changing; the current aim is to reduce major atherosclerotic cardiovascular events. In the cardiovascular outcome trials, despite being of the same class, they did not exert equivalent effects on cardiovascular disease.

Thus, it might not be simple to use these antidiabetic drugs in clinical practice, because the same class of drug cannot be grouped as equally effective in terms of preventing cardiovascular disease.

All SGLT2 inhibitors tested in the cardiovascular outcome trials reduced hospitalization for heart failure by 27–39% in diabetes patients, regardless of any history of heart failure. The indications for dapagliflozin and empagliflozin have been broadened, because both drugs slow heart failure and cardiovascular death in patients with reduced ejection fractions irrespective of diabetes. Empagliflozin and canagliflozin greatly reduce the incidences of major atherosclerotic cardiovascular events. In real-world settings, SGLT2 inhibitors are more effective than dipeptidyl peptidase-4 inhibitors for cardiovascular disease treatment in patients with shorter durations of diabetes.

Five GLP-1R agonists (liraglutide, semaglutide, albiglutide, dulaglutide and efegluconatide) significantly reduce the incidences of major atherosclerotic cardiovascular events in patients with type 2 diabetes who have established cardiovascular disease or a high risk of such disease; however, lixisenatide and extended-release exenatide do not reduce these incidences. Such protective effects of GLP-1R agonists on cardiovascular disease might be associated with decreases in the various cardiovascular risks and direct effects on the heart and endothelium. However, the GLP-1R agonists differ in terms of their effects on cardiovascular outcomes, perhaps reflecting differences in their durations of actions or extents of GLP-1R downregulation. The effects of GLP-1R agonists on cardiovascular disease must be considered individually; it is inappropriate to group the results to derive class effects. Inflammation caused by chronic hyperglycemia and diabetes-related dyslipidemia contributes to endothelial dysfunction and atherosclerosis progression. Patients with diabetes have shorter life expectancies because of increased...
mortality and cardiovascular disease. Multifactorial risk management of cardiovascular disease should be a main part of diabetes care, commencing when diabetes is first diagnosed. Physicians should consider immediate prescription of SGLT2 inhibitors or GLP-1R agonists with clear benefits in type 2 diabetes with cardiovascular disease. The prescription rate of SGLT2 inhibitors increased from 1% in 2013 to 14% in 2019, and the prescription rate of GLP-1R agonists did not change from 10% in 2013 to 10% in 2019 (Hawkins Gay, 2020 unpublished data). Considering that one in three patients with type 2 diabetes has comorbid cardiovascular disease, clinical inertia might be in the use of SGLT2 inhibitors or GLP-1R agonists. Such inertia has been previously noted in the context of glycemic control. In conclusion, it is essential to manage the cardiovascular risk factors of diabetes patients, and to select drugs indicated by recent research results and revised clinical guidelines (Figure 1).

**DISCLOSURE**

The authors declare no conflict of interest.

Approval of the research protocol: N/A.

Informed consent: N/A.

Approval date of registry was 7 November 2017 and the registration no. of the study/trial: N/A.

**REFERENCES**

1. Rodriguez-Gutierrez R, Gonzalez-Gonzalez JG, Zuñiga-Hernandez JA, *et al*. Benefits and harms of intensive glycemic control in patients with type 2 diabetes. *BMJ* 2019; 367: i5887.

2. Skyler JS, Bergenstal R, Bonow RO, *et al*. Intensive glycemic control and the prevention of cardiovascular events: Implications of the accord, advance, and va diabetes trials: A position statement of the American diabetes association and a scientific statement of the American college of cardiology foundation and the American heart association. *Circulation* 2009; 119: 351–357.

3. Lin CH, Chang CH, Chuang LM. Commentary on risk factors for first and subsequent cardiovascular disease events in type 1 diabetes: the diabetes control and complications trial/epidemiology of diabetes interventions and complications study. *J Diabetes Investig* 2021; 12: 313–316.

4. Yokote K, Suzuki R, Gouda M, *et al*. Association between glycemic control and cardiovascular events in older Japanese adults with diabetes mellitus: an analysis of the Japanese medical administrative database. *J Diabetes Investig* 2021; 12: 2036–2045.

5. Einerson TR, Acs A, Ludwig C, *et al*. Prevalence of cardiovascular disease in type 2 diabetes: a systematic literature review of scientific evidence from across the world in 2007–2017. *Cardiovasc Diabetol* 2018; 17: 83.

6. Park JH, Ha KH, Kim BY, *et al*. Trends in cardiovascular complications and mortality among patients with diabetes in South Korea. *Diabetes Metab J* 2021; 45: 120–124.

7. Di Angelantonio E, Kaptoge S, Wormser D, *et al*. Association of cardiometabolic multimorbidity with mortality. *JAMA* 2015; 314: 52–60.

8. Lee Y-B, Han K, Kim B, *et al*. Risk of early mortality and cardiovascular disease according to the presence of recently diagnosed diabetes and requirement for insulin treatment: a nationwide study. *J Diabetes Investig* 2021; 12: 1855–1863.

9. American Diabetes Association. 10. Cardiovascular disease and risk management: standards of medical practice. 

---

**To prevent cardiovascular disease in patients with type 2 diabetes**

| Traditional approach |
|----------------------|
| ✓ Glycemic control   |
| ✓ Blood pressure control |
| ✓ Lipid control      |
| ✓ Cessation of smoking |
| ✓ Obesity control    |

| New approach |
|--------------|
| ✓ Use of anti-diabetic drugs with the evidence of cardiovascular protection (SGLT2) or GLP-1R agonists |
| ✓ Avoid hypoglycemia |
| ✓ Reduce glycemic variability |
| ✓ Overcome clinical inertia |

Figure 1 | Approach to prevent cardiovascular disease in patients with type 2 diabetes. This summarized multifaceted approaches to reducing the risk of cardiovascular disease in patients with type 2 diabetes.

Animal studies: N/A.

Ja Young Jeon, Dae Jung Kim*
Department of Endocrinology and Metabolism, Ajou University School of Medicine, Suwon, Korea

© 2021 The Authors. Journal of Diabetes Investigation published by AASD and John Wiley & Sons Australia, Ltd

http://wileyonlinelibrary.com/journal/jdi

Cardiovascular disease in diabetes
10. Coles B, Zaccardi F, Ling S, et al. Cardiovascular events and mortality in people with and without type 2 diabetes: an observational study in a contemporary multi-ethnic population. *J Diabetes Investig* 2021; 12: 1175–1182.

11. Nishioka Y, Okada S, Noda T, et al. Absolute risk of acute coronary syndrome after severe hypoglycemia: a population-based 2-year cohort study using the national database in Japan. *J Diabetes Investig* 2020; 11: 426–434.

12. Gorst C, Kwok CS, Aslam S, et al. Long-term glycemic variability and risk of adverse outcomes: a systematic review and meta-analysis. *Diabetes Care* 2015; 38: 2354–2369.

13. Yamamoto H, Shinke T, Otake H, et al. Impact of daily glucose fluctuations on cardiovascular outcomes after percutaneous coronary intervention for patients with stable coronary artery disease undergoing lipid-lowering therapy. *J Diabetes Investig* 2021; 12: 1015–1024.

14. Sato M, Inaishi J, Saisho Y, et al. Association of visit-to-visit glycemic variability with risk of cardiovascular diseases in high-risk Japanese patients with type 2 diabetes: a subanalysis of the empathy trial. *J Diabetes Investig* 2021; 12: 2190–2196.

15. Cavalot F. Do data in the literature indicate that glycaemic variability is a clinical problem? Glycaemic variability and vascular complications of diabetes. *Diabetes Obes Metab* 2013; 15: 3–8.

16. Brown E, Heerspink HJL, Cuthbertson DJ, et al. Sglt2 inhibitors and glp-1 receptor agonists: established and emerging indications. *Lancet* 2021; 398: 262–276.

17. Kashiwagi A, Araki S, Maegawa H. Sodium-glucose cotransporter 2 inhibitors represent a paradigm shift in the prevention of heart failure in type 2 diabetes patients. *J Diabetes Investig* 2021; 12: 6–20.

18. Li HY. Sodium-glucose cotransporter 2 inhibitors: a drug with antidiabetic and cardioprotective properties. *J Diabetes Investig* 2021; 12: 310–312.

19. Jeon JY, Ha KH, Kim DJ. Cardiovascular safety of sodium glucose cotransporter 2 inhibitors as add-on to metformin monotherapy in patients with type 2 diabetes mellitus. *Diabetes Metab J* 2021; 45: 505–514.

20. Giugliano D, Scappaticcio L, Longo M, et al. Glp-1 receptor agonists and cardiorenal outcomes in type 2 diabetes: an updated meta-analysis of eight cvots. *Cardiovasc Diabetol* 2021; 20: 189.

21. Cornell S. A review of glp-1 receptor agonists in type 2 diabetes: a focus on the mechanism of action of once-weekly agents. *J Clin Pharm Ther* 2020; 45: 17–27.

22. Kimura T, Kaku K. New prospects for incretin-related drugs in the treatment of type 2 diabetes. *J Diabetes Investig* 2021; 12: 1141–1143.

23. Maegawa H, Ishigaki Y, Langer J, et al. Clinical inertia in patients with type 2 diabetes treated with oral antidiabetic drugs: results from a Japanese cohort study (jddm53). *J Diabetes Investig* 2021; 12: 374–381.

Doi: 10.1111/jdi.13742